A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

298

Participants

Timeline

Start Date

April 30, 1999

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions
Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Interventions
DRUG

Daclizumab

daclizumab 1 mg/kg/dose every 14 days for 5 doses

Trial Locations (24)

14853

Cornell University, Ithaca

20010

Washington Hospital, Washington D.C.

20742

University of Maryland, College Park

23298

Medical College of Virginia, Richmond

27708

Duke University, Durham

28203

Carolina Medical Center, Charlotte

29425

Medical University of South Carolina, Charleston

30322

Emory University, Atlanta

33124

University of Miami, Miami

38163

University of Tennessee, Memphis

43210

Ohio State University, Columbus

52242

University of Iowa, Iowa City

53226

Medical College of Wisconsin, Milwaukee

53705

University of Wisconsin, Madison

55455

University of Minnesota, Minneapolis

60208

Northwestern University, Chicago

60637

University of Chicago, Chicago

76798

Baylor University, Waco

77030

University of Texas - Houston, Houston

90095

University of California - Los Angeles, Los Angeles

95616

University of California - Davis, Davis

97239

Oregon Health Science University, Portland

98195

University of Washington, Seattle

M5G 2C4

Toronto Hospital, Toronto

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

collaborator

University of Tennessee

OTHER

lead

University of Cincinnati

OTHER